Nuvectis Pharma, Inc.
NasdaqCM · USDNuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Analytick AI is a research platform. Output is informational and not financial advice — trade at your own risk.
Analytick AI is a product of Analytick Inc. · Rockville, Maryland, 20852, United States
© 2026 Analytick AI
Be the first to share your outlook and start the conversation with other investors in the NVCT community.